Skip to main content

Table 1 Baseline patients’ characteristics by incident deterioration in glucose tolerance

From: Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study

Variable Deterioration in glucose tolerance (n = 24) No deterioration in glucose tolerance (n = 56) P value
Age (years) 57 ± 11 54 ± 10 0.32
BMI (kg/m2) 28.1 ± 4.1 26.6 ± 3.4 0.11
Current smokers, n (%) 5 (21%) 15 (27%) 0.57
one-vessel/multivessel CAD, n (%) 5/19 (21/79%) 16/40 (29/71%) 0.47
Left ventricular ejection fraction (%) 71 ± 6 70 ± 5 0.49
Hypertension, n (%) 20 (83%) 42 (75%) 0.42
Mean blood pressure (mm Hg) 95 ± 8 96 ± 9 0.85
Estimated GFR (mL/min per 1.73 m2) 71 ± 10 68 ± 12 0.26
LDL cholesterol (mmol/L) 2.5 ± 0.8 2.6 ± 0.7 0.79
HDL cholesterol (mmol/L) 0.8 ± 0.3 0.9 ± 0.4 0.22
Triglycerides (mmol/L) 1.5 ± 0.8 1.3 ± 0.7 0.40
Hs-CRP (mg/L) 1.9 (0.6–9.1) 1.6 (0.5–8.6) 0.16*
Fasting glucose (mmol/L) 6.0 ± 0.8 5.7 ± 0.8 0.17
Fasting insulin (μU/ml) 13.5 (4.9–50.2) 12.4 (5.3–43.5) 0.04*
HOMA-IR index 3.50 (1.78–13.8) 3.06 (1.44–10.7) 0.03*
ADMA (μmol/L) 0.53 ± 0.14 0.46 ± 0.10 0.02
SDMA (μmol/L) 0.64 ± 0.15 0.68 ± 0.13 0.27
L-arginine (μmol/L) 68 ± 19 67 ± 20 0.86
Drugs besides aspirin + ACEI + statin    
β-blockers, n (%) 17 (71%) 45 (80%) 0.35
Long-acting nitrates, n (%) 23 (96%) 50 (89%) 0.34
Calcium channel blockers, n (%) 8 (33%) 15 (27%) 0.55
  1. Data are shown as mean ± SD, median (range) or n (%).
  2. * By Student’s t-test for log-transformed data.
  3. By Welch’s t-test for unequal variances.
  4. Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ADMA, asymmetric dimethylarginine; BMI, body-mass index; CAD, coronary artery disease; GFR, glomerular filtration rate; HDL, high-density lipoproteins; HOMA-IR, homeostasis model assessment for insulin resistance; Hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoproteins; SDMA, symmetric dimethylarginine.